Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $4.74, but opened at $4.60. Tango Therapeutics shares last traded at $4.64, with a volume of 762,534 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $12.20.
Get Our Latest Report on TNGX
Tango Therapeutics Price Performance
The business's fifty day moving average price is $1.95 and its 200 day moving average price is $2.41. The stock has a market cap of $537.74 million, a P/E ratio of -4.22 and a beta of 1.24.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $5.39 million during the quarter, compared to the consensus estimate of $6.73 million. On average, analysts predict that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tango Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. TCG Crossover Management LLC purchased a new position in Tango Therapeutics in the fourth quarter valued at about $33,174,000. Boxer Capital Management LLC bought a new position in Tango Therapeutics in the 4th quarter valued at $32,077,000. Gilead Sciences Inc. purchased a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $15,000,000. Farallon Capital Management LLC bought a new position in shares of Tango Therapeutics in the 4th quarter worth $12,360,000. Finally, Nantahala Capital Management LLC purchased a new position in Tango Therapeutics in the fourth quarter worth $8,666,000. Institutional investors and hedge funds own 78.99% of the company's stock.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
